Skip to main content
. Author manuscript; available in PMC: 2024 Mar 14.
Published in final edited form as: Urol Oncol. 2022 Oct 26;41(1):51.e25–51.e31. doi: 10.1016/j.urolonc.2022.08.013

Table 4.

Multivariable analysis evaluating the risk of death among subgroup of patients who received first-line ICI therapy.

Feature Hazard ratio 95% Confidence ratio P Value
Cytoreductive nephrectomy 0.19 0.09–0.43 <0.0001
Histology
 Clear cell 1.0 (reference) - -
 Non-clear cell 3.18 0.65–15.5 0.15
 Other/Unknown 1.57 0.73–3.38 0.25
Total metastatic sites
 Only 1 1.0 (reference) - -
 2 or more 1.84 0.87–3.90 0.11
Age at metastatic diagnosis 1.00 0.97–1.04 0.8
IMDC risk score
 Favorable 1.0 (reference) - -
 Intermediate 1.91 0.24–15.4 0.5
 Poor 1.86 0.23–15.0 0.6